Canada H7V 4A7, Tel. 5/12/20 at 1:00 PM EDT Listen to Webcast. Here’s what analysts think will happen to its price in the coming time. Raw Stochastic average of BELLUS Health Inc. in the period of last 50 days is set at 64.71%. Who are BELLUS Health's key executives? BELLUS Health Inc. (BLU) saw downtrend of -2.55% in the recent trading with $3.82 being its most recent. – Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim analysis expected in mid-2021 -. Several reasons you should own SonosInc (SONO). Recent Change of 7.46% in the BELLUS Health Inc. (BLU) market price... Get the hottest stocks to trade every day before the market opens 100% free. The 1-year high price for the company’s stock is recorded $4.96 on 02/18/21, with the lowest value was $2.94 for the same time period, recorded on 01/05/21. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019. BELLUS Health Inc. (NASDAQ:BLU) went up by 10.84% from its latest closing price compared to the recent 1-year high of $12.03. 5/27/20 at 9:00 AM EDT Listen to Webcast. Stock in Bellus slumped 72 per cent on Monday after reporting its first human trial results for 68 patients. We do not sell or share your information with anyone. LAVAL, Quebec-- (BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr... Business Wire - 3 months ago. At the very opening of the session, the stock price was $3.90 and reached a high price of $4.18, prior to closing the session it reached the value of $3.89. How will Spotify benefit from an ever-growing Indian population? It’s free. These forward-looking statements speak only as of the date made, and BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. When it comes to the year-to-date metrics, the BELLUS Health Inc. (BLU) recorded performance in the market was 36.60%, having the revenues showcasing 32.70% on a quarterly basis in comparison with the same period year before. Feb. 25, 2021 5:45 PM ET BELLUS Health Inc. (BLU) By: Akanksha Bakshi, SA News Editor. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. BELLUS Health Reports Year 2020 Financial Results and Business Highlights. Even if you’re not actively in crypto, you deserve to know what’s actually going on...
You have entered an incorrect email address! Investchronicle.com is an Economic news website, which offers broad information about the Stock markets and Equities. - Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim analysis expected in mid-2021 - - Initiated the Phase 2 BLUEPRINT clinical trial in chronic pruritus associated with atopic dermatitis; topline results expected Q4 2021 - -, LAVAL, Quebec --(BUSINESS WIRE)--Feb. 22, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced, LAVAL, Quebec --(BUSINESS WIRE)--Jan. 14, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today, BELLUS Health Reports Year 2020 Financial Results and Business Highlights, BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences, BELLUS Health to Present at the Eleventh International Virtual Cough Symposium. //-->